The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

Rahway, New Jersey Tuesday, January 28, 2025, 10:00 Hrs [IST] ...

Spear and Griswald 9 reported the first case of a fall in blood pressure after the administration of dibenamine (N, N-dibenzyl-β-chloroethylamine) to a patient who proved at operation to have a ...

Family history or certain types of symptom profiles might indicate to a doctor that a pheochromocytoma may be present. These tumors are also linked to certain, rare genetic conditions. Diagnosis ...

Gao, F. (2025) Research on the Causes and Preventive Measures of Pregnancy Complicated by Acute Abdomen. Open Journal of Obstetrics and Gynecology, 15, 97-107. doi: 10.4236/ojog.2025.151010 .

During his time in Columbus, Dr. Miller published an illustrated book, “Principles of Health Preservation”, which observed ...

focused on the evaluation of postoperative management of patients with pheochromocytoma assessing hemodynamic ... that since PPGL recurrence can occur at any time after the initial diagnosis of PPGL, ...

The FDA has accepted the application for belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.